LOC388553 Inhibitors
LOC388553 inhibitors encompass a broad spectrum of chemical compounds that inhibit various cellular signaling pathways which could be indirectly involved in the functional activity of LOC388553. The PI3K/AKT pathway is a central signaling node in many cellular processes, and inhibitors like Wortmannin and LY294002 serve to block this pathway, potentially leading to decreased LOC388553 activity if it is regulated downstream of AKT. Similarly, the inhibition of mTOR by Rapamycin would affect protein synthesis and cell growth, possibly leading to the downregulation of LOC388553 if it is involved in these pathways.
Inhibition of the MAPK/ERK pathway by compounds like U0126 and PD98059 could lead to decreased LOC388553 activity, assuming LOC388553 is modulated by ERK signaling. The JNK and p38 MAPK pathways, targeted by SP600125 and SB203580 respectively, are other potential indirect routes for diminishing LOC388553 activity if LOC388553 operates downstream of these kinases. PP2 and Dasatinib target Src family kinases, with Dasatinib also inhibiting Bcr-Abl and c-Kit. If LOC388553 is activated by these kinases, their inhibition could result in decreased LOC388553 activity.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
PI3K inhibitor that prevents activation of downstream AKT signaling. Inhibition of PI3K by Wortmannin would reduce AKT-mediated phosphorylation events, potentially leading to decreased LOC388553 activity if LOC388553 is downstream of AKT. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
Another PI3K inhibitor that blocks the PI3K/AKT pathway. LY294002's inhibition of PI3K can decrease downstream signaling, possibly leading to reduced activity of LOC388553 if it is regulated by this pathway. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
mTOR inhibitor that disrupts the mTORC1 complex, leading to reduced protein synthesis and cell proliferation. Rapamycin could decrease LOC388553 activity if LOC388553 is involved in mTORC1-regulated processes. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
MEK inhibitor that impedes the MAPK/ERK pathway. By blocking MEK, U0126 could lead to reduced ERK activity and thus decrease LOC388553 activity if LOC388553 is modulated by the MAPK/ERK pathway. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
JNK inhibitor that blocks the JNK signaling pathway. Inhibition of JNK by SP600125 could decrease LOC388553 activity if LOC388553 is a downstream effector of JNK signaling. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
p38 MAPK inhibitor that prevents p38-mediated signaling. SB203580 inhibition of p38 MAPK could result in reduced LOC388553 activity if LOC388553 is within the p38 MAPK signaling cascade. | ||||||
PP 2 | 172889-27-9 | sc-202769 sc-202769A | 1 mg 5 mg | $94.00 $227.00 | 30 | |
Src family kinase inhibitor that impairs Src kinase signaling. PP2 could decrease LOC388553 activity if LOC388553 is activated by Src family kinases. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
MEK inhibitor that disrupts the MAPK/ERK pathway. PD98059 could reduce LOC388553 activity if LOC388553 is dependent on ERK signaling for its function. | ||||||
Leflunomide | 75706-12-6 | sc-202209 sc-202209A | 10 mg 50 mg | $20.00 $83.00 | 5 | |
DHODH inhibitor that affects pyrimidine synthesis. By inhibiting de novo pyrimidine synthesis, Leflunomide could decrease LOC388553 activity if LOC388553 relies on rapid nucleotide synthesis for its function. | ||||||
Imatinib | 152459-95-5 | sc-267106 sc-267106A sc-267106B | 10 mg 100 mg 1 g | $26.00 $119.00 $213.00 | 27 | |
Bcr-Abl tyrosine kinase inhibitor that also inhibits PDGFR and c-Kit. Imatinib could reduce LOC388553 activity if LOC388553 is activated downstream of these kinases. | ||||||